1010002406 Controlled Trial of 3 4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (LEMS)



Study Overview

The overall purpose is to provide children access to 3,4-DAP, which is not currently approved by the FDA for use in the United States.


Study Description

This study is designed to provide 3,4-DAP to patients with Lambert-Eaton Myasthenic Syndrome (LEMS) in attempt to improve their quality of life.

Research Study Identifier: TX1285
ClinicalTrials.gov Identifier: NCT1010002406


Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.